Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Sensitivity and Resistance to Leukemia

In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development

Leukemia volume 17, pages 1338–1343 (2003)Cite this article

Abstract

To determine the potential of aplidin as a cytotoxic agent in pediatric leukemia, we tested bone marrow (BM) and peripheral blood (PB) samples (n=72) of children with different types of leukemia and healthy children in the methyl-thiazol-tetrazolium assay. Also, we compared these results with other cytotoxic drugs. Aplidin was cytotoxic in vitro at nanomolar concentrations, in a dose-dependent fashion. L-carnitine, that is applied in clinical studies to prevent myotoxicity caused by aplidin, had no effect on aplidin cytotoxicity in vitro. Aplidin cytotoxicity in vitro was not different when initial and relapsed acute lymphoblastic leukemia (ALL) or initial ALL and initial acute myeloid leukemia were compared. However, normal BM (n=19) and PB (n=13) cells were more resistant to aplidin than leukemic cells (median two- to seven-fold, P=0.001 and median four- to 11-fold, P<0.0001, respectively). In leukemia samples, no significant crossresistance between aplidin and other cytotoxic drugs was found, except for a trend for correlation with 2′,2′-difluorodeoxycytidine (ρ=0.71, P=0.02). In normal BM samples, significant crossresistance with the epipodophyllotoxins was found, which is not readily explained by the currently known mechanisms of action of aplidin. In conclusion, we show that aplidin has selective cytotoxicity in vitro towards childhood leukemia cells and generally lacks crossresistance with other known cytotoxic drugs, which warrants clinical studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Rinehart KL, Lithgow-Berelloni AM . Novel antiviral and cytotoxic agent. PCT Int. Pat. Appl. WO 91.04985, April 18, 1991; GB Appl. 89/22,026, September 29, 1989; Chem Abstr 1991; 115: 248086q.

    Google Scholar 

  2. Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR . In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer 1998; 78: 739–744.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Faircloth G, Grant W, Nam S, Jimeno J, Manzanares I, Rinehart K . Schedule-dependency of aplidine, a marine depsipeptide with antitumor activity. Proc Am Assoc Cancer Res 1999; 40: 394.

    Google Scholar 

  4. Paz-Ares L, Anthony A, Pronk L, Twelves C, Alonso S, Cortes-Funes H et al. Phase I clinical and pharmacokinetic study of aplidine, a new marine didemnin, administered as 24-hour infusion weekly. Clin Cancer Res 2000; 6(Suppl): 4509.

    Google Scholar 

  5. Raymond E, Ady-Vago N, Baudin E, Ribrag V, Faivre S, Lecot F et al. A phase I and pharmacokinetic study of aplidine given as a 24-hour continuous infusion every other week in patients with solid tumor and lymphoma. Clin Cancer Res 2000; 6(Suppl): 4510.

    Google Scholar 

  6. Maroun J, Belanger K, Seymour L, Soulieres D, Charpentier D, Goel R et al. Phase I study of aplidine in a 5 day bolus q 3 weeks in patients with solid tumors and lymphomas. Clin Cancer Res 2000; 6(Suppl): 4509.

    Google Scholar 

  7. Izquierdo MA, Bowman A, Martinez M, Cicchella B, Jimeno J, Guzman C et al. Phase I trial of aplidine given as a 1 hour intravenous weekly infusion in patients with advanced solid tumors and lymphoma. Clin Cancer Res 2000; 6(Suppl): 4509.

    Google Scholar 

  8. Broggini M, Marchini S, D'Incalci M, Taraboletti G, Giavazzi R, Faircloth G et al. Aplidine blocks VEGF secretion and VEGF/VEGF-R1 autocrine loop in a human leukemic cell line. Clin Cancer Res 2000; 6(Suppl): 4509.

    Google Scholar 

  9. Erba E, Bassano L, Di Liberti G, Muradore I, Chiorino G, Ubezio P et al. Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. Br J Cancer 2002; 86: 1510–1517.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Crews CM, Collins JL, Lane WS, Snaper ML, Schreiber SL . GTP-dependent binding of the antiproliferative agent Didemnin to elongation factor 1-alpha. J Biol Chem 1994; 269: 15411–15414.

    CAS  PubMed  Google Scholar 

  11. Urdiales JL, Morata P, Nunez de Castro I, Sánchez-Jiménez F . Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett 1996; 102: 31–37.

    Article  CAS  PubMed  Google Scholar 

  12. Crews CM, Lane WS, Schreiber SL . Didemnin binds to the palmitoyl protein thioesterase responsible for infantile neuronal ceroid lipofuscinosis. Proc Natl Acad Sci USA 1996; 93: 4316–4319.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Erba E, Ronzoni S, Bergamaschi D, Bassano L, Desiderio MA, Faircloth G et al. Mechanism of antileukemic activity of Aplidine. Proc Am Assoc Cancer Res 1999; 40: 3.

    Google Scholar 

  14. Kaspers GJL, Pieters R, van Zandtwijk CH, Hählen K, van Wering ER, Veerman AJP . Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leukemia Res 1995; 19: 175–181.

    Article  CAS  Google Scholar 

  15. Kaspers GJL, Veerman AJP, Pieters R, van Zantwijk CH, Smets LA, van Wering ER et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997; 90: 2723–2729.

    CAS  PubMed  Google Scholar 

  16. Kaspers GJL, Pieters R, van Zantwijk CH, van Wering ER, van der Does-van den Berg A, Veerman AJP . Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro–vivo correlations and crossresistance to other drugs. Blood 1998; 92: 259–266.

    CAS  PubMed  Google Scholar 

  17. Pieters R, Klumper E, Kaspers GJL, Veerman AJP . Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit Rev Hematol/Oncol 1997; 25: 11–26.

    Article  CAS  Google Scholar 

  18. Zwaan CM, Kaspers GJL, Pieters R, Ramakers-van Woerden NL, den Boer ML, Wünsche R et al. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 2000; 96: 2879–2886.

    CAS  PubMed  Google Scholar 

  19. Kaspers GJL, Pieters R, Van Zantwijk CH, de Laat PA, de Waal FC, van Wering ER et al. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukemic cells from bone marrow and peripheral blood. Br J Cancer 1991; 64: 469–474.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Pieters R, Huismans DR, Leyva A, Veerman AJP . Adaptation of the rapid automated tetrazolium dye based (MTT-) assay for chemosensitivity testing in childhood leukemia. Cancer Lett 1988; 41: 323–332.

    Article  CAS  PubMed  Google Scholar 

  21. Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MW, Heyenbrok MW et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327–2336.

    CAS  PubMed  Google Scholar 

  22. Kaspers GJ, Veerman AJ . Clinical significance of cellular drug resistance in childhood leukemia. Recent Results Cancer Res 2003; 161: 196–220.

    Article  CAS  PubMed  Google Scholar 

  23. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R . In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 1997; 89: 2959–2965.

    CAS  PubMed  Google Scholar 

  24. Asselin BL, Kreissman S, Coppola DJ, Bernal SD, Leavitt PR, Gelber RD et al. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1999; 21: 6–12.

    Article  CAS  PubMed  Google Scholar 

  25. Yamada S, Hongo T, Okada S, Watanabe C, Fujii Y, Ohzeki T . Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia 2001; 15: 1892–1897.

    Article  CAS  PubMed  Google Scholar 

  26. Klumper E, Pieters R, Veerman AJP, Huismans DR, Loonen AH, Hählen K et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995; 86: 3861–3868.

    CAS  PubMed  Google Scholar 

  27. Albella B, Faircloth G, López-Lázaro L, Guzmán C, Jimeno J, Bueren JA . In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results. Eur J Cancer 2002; 38: 1395–1404.

    Article  CAS  PubMed  Google Scholar 

  28. Nabhan C, Krett N, Gandhi V, Rosen S . Gemcitabine in hematologic malignancies. Curr Opin Oncol 2001; 13: 514–521.

    Article  CAS  PubMed  Google Scholar 

  29. Steinherz PG, Seibel NL, Ames MM, Avramis VI, Krailo MD, Liu-Mares W et al. Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group. Leukemia Lymphoma 2002; 43: 1945–1950.

    Article  CAS  PubMed  Google Scholar 

  30. Rizzieri DA, Bass AJ, Rosner GL, Gockerman JP, DeCastro CM, Petros WP et al. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol 2002; 20: 674–679.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the laboratory technicians of the research laboratory of Pediatric Oncology of the VU University Medical Center for their help with performing the MTT assays.

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology/Oncology, VU University Medical Center, Amsterdam, The Netherlands

    D Bresters, A J F Broekhuizen, P Kaaijk & G J L Kaspers

  2. Department of Pediatric Immunology, Hematology, Oncology, Bone Marrow Transplantation and Auto-immune Diseases, Leiden University Medical Center, Leiden, The Netherlands

    D Bresters

  3. PharmaMar SA, Research and Development, Tres Cantos (Madrid), Spain

    G T Faircloth

  4. PharmaMar USA, Inc., Cambridge, MA, USA

    J Jimeno

Authors
  1. D Bresters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A J F Broekhuizen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Kaaijk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G T Faircloth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Jimeno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G J L Kaspers
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bresters, D., Broekhuizen, A., Kaaijk, P. et al. In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development. Leukemia 17, 1338–1343 (2003). https://doi.org/10.1038/sj.leu.2402972

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402972

Keywords

This article is cited by

Search

Advanced search

Quick links